Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477535 | 0.82 | KMT2A (0.32) | KMT2AMEN1ALDH1A1HPGDATM | |
| SCHEMBL6486971 | 0.66 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1HPGDATM | |
| SCHEMBL6488688 | 0.65 | KMT2A (0.34) | KMT2AMEN1ALDH1A1HPGDATM | |
| SCHEMBL6477202 | 0.65 | KMT2A (0.34) | KMT2AMEN1ALDH1A1HPGDATM | |
| SCHEMBL8625450 | 0.64 | SRD5A2 (0.47) | VCP | |
| SCHEMBL402518 | 0.59 | RARB (0.62) | CYP3A4 | |
| SCHEMBL9300890 | 0.58 | MAPT (0.46) | ALDH1A1HPGDVCPMAPT | |
| SCHEMBL28533557 | 0.57 | MAPT (0.42) | ALDH1A1HPGDCYP3A4MAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL2707922 | 0.57 | RARB (0.60) | CYP3A4 | |
| SCHEMBL9578548 | 0.57 | MAPT (0.43) | KMT2AMEN1ALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | KMT2A 2335/4885MEN1 3457/4885ALDH1A1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.